US Stock MarketDetailed Quotes

ZBIO Zenas BioPharma

Watchlist
  • 21.000
  • +0.080+0.38%
Close Nov 8 16:00 ET
  • 21.000
  • 0.0000.00%
Post 16:00 ET
877.33MMarket Cap-14695P/E (TTM)

Zenas BioPharma Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
50M
0
50M
0
0
0
0
Operating revenue
--0
--0
--50M
--0
--50M
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
110.01%39.7M
44.49%27.58M
2.59%77.15M
30.49%24.78M
14.38M
18.91M
19.09M
75.2M
18.99M
Selling and administrative expenses
47.74%5.9M
31.93%4.93M
26.68%17.11M
35.27%4.36M
--5.02M
--3.99M
--3.74M
--13.51M
--3.22M
-General and administrative expense
47.74%5.9M
31.93%4.93M
26.68%17.11M
35.27%4.36M
--5.02M
--3.99M
--3.74M
--13.51M
--3.22M
Research and development costs
126.66%33.81M
47.55%22.65M
-2.68%60.03M
29.51%20.42M
--9.35M
--14.92M
--15.35M
--61.69M
--15.77M
Operating profit
-110.01%-39.7M
-44.49%-27.58M
63.90%-27.15M
-30.49%-24.78M
35.62M
-18.91M
-19.09M
-75.2M
-18.99M
Net non-operating interest income expense
Other net income (expense)
117.01%1.73M
-1,918.18%-222K
78.05%-9.68M
9,960.00%493K
-16K
-10.14M
-11K
-44.08M
-5K
Gain on sale of security
----
----
----
----
----
----
----
---13.27M
--0
Special income (charges)
----
----
-900.00%-10M
--0
--0
----
----
---1M
--0
-Less:Other special charges
----
----
900.00%10M
--0
--0
----
----
--1M
--0
Other non- operating income (expenses)
1,314.79%1.73M
-1,918.18%-222K
101.09%324K
9,960.00%493K
---16K
---142K
---11K
---29.82M
---5K
Income before tax
-30.74%-37.98M
-45.57%-27.8M
69.13%-36.82M
-27.86%-24.29M
35.61M
-29.05M
-19.1M
-119.28M
-18.99M
Income tax
301K
0
Net income
-30.74%-37.98M
-45.57%-27.8M
68.88%-37.12M
-29.45%-24.59M
35.61M
-29.05M
-19.1M
-119.28M
-18.99M
Net income continuous Operations
-30.74%-37.98M
-45.57%-27.8M
68.88%-37.12M
-29.45%-24.59M
--35.61M
---29.05M
---19.1M
---119.28M
---18.99M
Minority interest income
Net income attributable to the parent company
-30.74%-37.98M
-45.57%-27.8M
68.88%-37.12M
-29.45%-24.59M
35.61M
-29.05M
-19.1M
-119.28M
-18.99M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-30.74%-37.98M
-45.57%-27.8M
68.88%-37.12M
-29.45%-24.59M
35.61M
-29.05M
-19.1M
-119.28M
-18.99M
Basic earnings per share
42.78%-0.9544
36.29%-0.6986
68.90%-2.88
-29.45%-1.4118
2.0445
-1.6678
-1.0965
-9.2613
-1.0906
Diluted earnings per share
42.78%-0.9544
36.29%-0.6986
68.90%-2.88
-29.45%-1.4118
2.0445
-1.6678
-1.0965
-9.2613
-1.0906
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0050M050M0000
Operating revenue --0--0--50M--0--50M--0--0--0--0
Cost of revenue
Gross profit
Operating expense 110.01%39.7M44.49%27.58M2.59%77.15M30.49%24.78M14.38M18.91M19.09M75.2M18.99M
Selling and administrative expenses 47.74%5.9M31.93%4.93M26.68%17.11M35.27%4.36M--5.02M--3.99M--3.74M--13.51M--3.22M
-General and administrative expense 47.74%5.9M31.93%4.93M26.68%17.11M35.27%4.36M--5.02M--3.99M--3.74M--13.51M--3.22M
Research and development costs 126.66%33.81M47.55%22.65M-2.68%60.03M29.51%20.42M--9.35M--14.92M--15.35M--61.69M--15.77M
Operating profit -110.01%-39.7M-44.49%-27.58M63.90%-27.15M-30.49%-24.78M35.62M-18.91M-19.09M-75.2M-18.99M
Net non-operating interest income expense
Other net income (expense) 117.01%1.73M-1,918.18%-222K78.05%-9.68M9,960.00%493K-16K-10.14M-11K-44.08M-5K
Gain on sale of security -------------------------------13.27M--0
Special income (charges) ---------900.00%-10M--0--0-----------1M--0
-Less:Other special charges --------900.00%10M--0--0----------1M--0
Other non- operating income (expenses) 1,314.79%1.73M-1,918.18%-222K101.09%324K9,960.00%493K---16K---142K---11K---29.82M---5K
Income before tax -30.74%-37.98M-45.57%-27.8M69.13%-36.82M-27.86%-24.29M35.61M-29.05M-19.1M-119.28M-18.99M
Income tax 301K0
Net income -30.74%-37.98M-45.57%-27.8M68.88%-37.12M-29.45%-24.59M35.61M-29.05M-19.1M-119.28M-18.99M
Net income continuous Operations -30.74%-37.98M-45.57%-27.8M68.88%-37.12M-29.45%-24.59M--35.61M---29.05M---19.1M---119.28M---18.99M
Minority interest income
Net income attributable to the parent company -30.74%-37.98M-45.57%-27.8M68.88%-37.12M-29.45%-24.59M35.61M-29.05M-19.1M-119.28M-18.99M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -30.74%-37.98M-45.57%-27.8M68.88%-37.12M-29.45%-24.59M35.61M-29.05M-19.1M-119.28M-18.99M
Basic earnings per share 42.78%-0.954436.29%-0.698668.90%-2.88-29.45%-1.41182.0445-1.6678-1.0965-9.2613-1.0906
Diluted earnings per share 42.78%-0.954436.29%-0.698668.90%-2.88-29.45%-1.41182.0445-1.6678-1.0965-9.2613-1.0906
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data